Could a common Blood-Flow drug tame rheumatoid arthritis?

NCT ID NCT06998628

Recruiting now Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 2 trial tests whether adding pentoxifylline (a drug usually used for blood flow) to standard methotrexate therapy can reduce inflammation in people with active rheumatoid arthritis. Fifty adults aged 18–70 with moderate-to-severe disease will receive the combination for a set period. The main goal is to see if their disease activity score (DAS28) improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pentoxifylline (a blood-flow medication) added to standard methotrexate therapy
What this could lead to: If it works, this could point toward a new, affordable add-on treatment to better control rheumatoid arthritis inflammation.
What could go wrong: This is a small, early Phase 2 trial with only 50 participants. Pentoxifylline is not a proven arthritis drug, and results may not lead to a new standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Faculty of Medicine, Al-Azhar University
RECRUITING

Damietta, Damietta Governorate, 34511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.